Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 139

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 6
Chunk 139
---
, 2024, the record date for the determination of shareholders and option holders
of Ceapro entitled to receive notice of and vote at Ceapro’s special meeting of shareholders and option holders held on March 12,
2024, the directors and officers of Ceapro subject to the Aeterna Zentaris Lock-Up Agreements held or exercised control or direction
over 1,990,468 Ceapro Shares, representing approximately 2.54% of the issued and outstanding Ceapro Shares, and 1,985,000 Ceapro Options
(as defined in the Arrangement Agreement), for a total of 3,975,468 Ceapro securities, representing 4.90% of the total issued and outstanding
Ceapro securities.

Symrise
Distribution agreement

The
Symrise Agreement is a supply and distribution agreement with Symrise AG with respect to the distribution and commercialization of Ceapro’s
high-value active ingredients to key international players in the cosmetics industry, effective from January 1, 2022 until December 31,
2026. Under the Symrise Agreement, Symrise AG is obligated to purchase minimum annual volumes of Ceapro’s products unless (i) there
is a force majeure event, or (ii) there is a decrease or cessation of any customer’s purchase of the products from Symrise due
to a formulation change by such customers, as more particularly set forth in the Symrise Agreement.

European
Economic Area and United Kingdom License Agreement

On
December 7, 2020, the Company entered into an exclusive licensing agreement with Consilient Health Limited (“ CH”) for the
commercialization of macimorelin (the “ Licensed Product”) in the European Economic Area and the United Kingdom (the “ CH
License Agreement”). On March 15, 2023, with the Company’s consent, Consilient Health (“ CH”) entered into an
assignment agreement with Pharmanovia to transfer the current licensing agreement for the commercialization of macimorelin in the European
Economic Area and the United Kingdom to Pharmanovia, as well as the current supply agreement pursuant to which the Company agreed to
provide the licensed product (together, the “ Assignment Agreement”). Also on March 15, 2023, the Company and Pharmanovia
entered into an amendment agreement, pursuant to which the Company provided its acknowledgement and consent to the Assignment Agreement
and agreed to certain amended terms which do not materially differ from the previous license and supply agreement with